



Pharmacology of HIV Treatment and Antivirals Against Hepatitis Viruses

Guest Editor:

Dr. José Vicente Fernández-Montero

Department of Internal Medicine,
Complejo Hospitalario
Universitario de Santiago (CHUS),
Santiago de Compostela, Spain

Deadline for manuscript
submissions:

closed (31 May 2025)

Message from the Guest Editor

Dear Colleagues,

Therapies for HIV infection and hepatitis C have significantly evolved in recent years. Newer antiretrovirals have overcome significant obstacles like side effects, high daily pill burden, lack of efficacy, resistances, or limited access to therapy, and now, most patients receive simple therapies, mostly consisting of single-tablet regimens or long-acting injectable drugs, achieving long-lasting virological response. Furthermore, HIV might also benefit from monoclonal antibodies, which may dramatically change HIV therapy as we currently know. Direct-acting antivirals for hepatitis C infection have radically changed millions of patients' lives worldwide, achieving remarkable efficacy with short, simple treatment regimens. This therapeutic revolution has turned a complex chronic infection with limited treatment options into an eradicable disease, as seen in several population-scale trials. The development of new antivirals for hepatitis B and D offers hope for patients seeking a cure.

This Special Issue aims to provide updated information on new antiretrovirals and antivirals against hepatitis viruses, as well as newer treatment strategies and drug delivery methods.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication
Program, Center for Cancer
Research, National Cancer
Institute, Frederick, MD 21702-
1201, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.**

Journal Rank: JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Contact Us

Viruses Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/viruses
viruses@mdpi.com
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)